Based on the results obtained from the various CVOTs, the administration of GLP-1 RAs with proven beneficial effects (i.e., liraglutide, semaglutide, and dulaglutide) is recommended by the American Diabetes Association (ADA) and the European Association for the study of Diabetes (EASD) for patients with T2DM and pre-established atherosclerotic CVD or at a high CV risk, where the benefit of these drugs is more enhanced [140]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.